



CASSS VIRTUAL SUMMIT

Tackling Bioconjugate Challenges

KNOWLEDGE SHARING AND CAPACITY BUILDING

- *Newer modalities require new science and regulatory approaches* to product and process understanding.
- Industry can *leverage deep molecule understanding, prior knowledge, and platform approaches* to frame science and risk-based justifications.
- Comparability assessments for ADCs need to *consider downstream impact*, such as the potential for a drug linker change to impact conjugation.
- Understanding the capability of methods and the use of orthogonal analytical methods can be *essential to detect and understand the impact of changes*.

VIRTUAL SUMMIT 2026 BY THE NUMBERS



Total Attendees

531



First-Time Attendees

231



Companies Represented

41



Regulatory Participation

4



Country Collaboration

18

Austria | Belgium | Canada | China | Denmark | France | Germany | India | Ireland | Italy | Japan | Netherlands | Singapore | South Korea | Spain | Switzerland | United Kingdom | United States

CASSS RESOURCES

Looking for more past meeting content?

Speaker slides, roundtable notes, and video presentations can be accessed through **Papers and Presentations** and **CASSS On Demand** on our website. www.casss.org